Pilot Study Evaluating Safety and Efficacy of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in OAB Patients
Phase of Trial: Phase I/II
Latest Information Update: 04 Mar 2016
At a glance
- Drugs Botulinum toxin (Primary)
- Indications Overactive bladder
- Focus Adverse reactions; Therapeutic Use
- Sponsors UroGen Pharma
- 29 Feb 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 31 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Nov 2015, according to ClinicalTrials.gov record.
- 31 Aug 2015 Planned End Date changed from 1 Aug 2015 to 1 Jun 2016 as per ClinicalTrials.gov record.